Werewolf Therapeutics(US:HOWL) Globenewswire·2025-05-05 12:00Company Overview - Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company focused on developing conditionally activated therapeutics to stimulate the immune system for cancer and other immune-mediated conditions [3] - The company utilizes its proprietary PREDATOR® platform to create molecules that selectively activate in the tumor microenvironment while remaining inactive in peripheral tissues [3] Product Development - Werewolf's advanced clinical stage product candidates include WTX-124 and WTX-330, which are conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively [3] - WTX-124 is being advanced in multiple tumor types both as a single agent and in combination with an immune checkpoint inhibitor, while WTX-330 is being developed for multiple tumor types or Non-Hodgkin Lymphoma as a single agent [3] Upcoming Events - Management will participate in the Citizens Life Sciences Conference on May 8, 2025, at 10:00 am ET in New York [2] - Management will also participate in the Bank of America Securities 2025 Health Care Conference on May 14, 2025, at 3:15 pm PT in Las Vegas [2] - Live webcasts for these events will be available, with archived replays accessible for approximately 90 days [2]